Strategic Initiative

Slingshot members are tracking this corporate initiative:

Ocular Therapeutics (OCUL) and Regeneron (REGN) Agree to Develop a Sustained-Release Formulation of Aflibercept for Wet Age-Related Macular Degeneration (Wet AMD)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Oct 13, 2016
Projected Implementation:
Q4, 2016
Relevance Tracked Until:
Q4, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Strategic Initiative, Aflibercept, Wet Age-related Macular Degeneration, Wet Amd, Sustained-release Formulation, Product Development